Profound Medical and Telix Pharmaceuticals Enter Co-Education Agreement to Advance PSMA-Informed Prostate Care
Collaboration will educate physicians and prostate cancer centers on the complementary roles of Telix’s PSMA-PET molecular imaging technologies and Profound’s MRI-guided TULSA-PRO® Agreement provides Profound with increased access to urologists via a strong strategic partner and creates a framework to further advance clinical evidence-based patient selection and optimization of patient treatment…
We haven't written up this one. Financial Post has the full story — the link below goes straight to it.
